Table 3.
Cancer site | No. of ca/co | Matching factorsa OR (95% CI) |
Multivariable adjustedb OR (95% CI) |
---|---|---|---|
Se, per 20 µg/L | |||
IHBC | 36/36 | 0.70 (0.39, 1.25) | 0.42 (0.15, 1.20) |
Gallbladderc | 41/41 | 0.50 (0.26, 0.97) | 0.55 (0.22, 1.37) |
Cholangiocarcinomad | 31/31 | 0.67 (0.37, 1.23) | 0.34 (0.10, 1.08) |
SePP, per 1.5 mg/L | |||
IHBC | 40/40 | 0.71 (0.43, 1.16) | 0.51 (0.21, 1.23) |
Gallbladder | 44/44 | 0.69 (0.37, 1.26) | 0.33 (0.08, 1.35) |
Cholangiocarcinoma | 35/35 | 0.74 (0.45, 1.22) | 0.51 (0.23, 1.22) |
Abbreviations: EPIC, European Prospective Investigation into Cancer and Nutrition; CI, confidence interval; IHBC, intrahepatic bile duct; OR, incidence rate ratio; Se, selenium; SePP, selenoprotein P.
ORs and 95% CI estimated by conditional logistic regression conditioned on the matching factors.
Additionally adjusted for body mass index (kg/m2, continuous), waist circumference (cm, continuous), baseline alcohol intake (g/d, continuous), physical activity (METs, continuous), smoking status (never, former, current, unknown), education (none/primary, technical/professional, secondary, university or higher), alcohol intake pattern (never drinkers, former drinkers, drinkers only at recruitment, always drinkers), self-reported diabetes, and total energy intake (kcal/d).
Gallbladder cancers were also included in the GBTC grouping (see table 2).
Cholangiocarcinoma cancers were also included in the GBTC (see table 2) and IHBC groupings.